In a prototypical model of multistage tumorigenesis involving pancreatic islets in RIP1-Tag2 transgenic mice, activation of insulin-like growth factor II (IGF-II) was previously shown to serve as a survival factor that inhibited apoptosis. Now IGF-1R, the receptor tyrosine kinase for IGF-II, has been found to be variably upregulated, first uniformly in dysplastic and angiogenic progenitors and then focally at the margins and in invasive regions of carcinomas. When the levels of IGF-1R were forcibly elevated throughout islet tumorigenesis, progression was accelerated at all stages in the pathway, although apoptosis was not differentially suppressed. Notably, encapsulated tumors were absent; instead, invasive carcinomas with downregulated E-cadherin were prevalent, and the majority of mice had local lymph node metastasis.
Introduction
focally upregulated as oncogene-expressing islet ␤ cells become hyperproliferative, populating hyperplastic and dysplastic pancreatic islets; IGF-II levels increase and become more uniReceptor tyrosine kinases are crucial intermediaries between the extracellular milieu and intracellular signaling pathways that form in the subsequent stages of angiogenic (dysplastic) islets and solid tumors (Christofori et al., 1994; Naik et al., 1994) . together control cellular functions as diverse as the cell division cycle, apoptosis, gene expression, cytoskeletal architecture, Knowledge of the role that IGF-II plays in this system came from studies with mice in which IGF-II is genetically ablated. cell adhesion, and cell migration. As the mechanisms controlling cell signaling are better understood, it has become clear that RIP1-Tag2, IGF-II null mice developed markedly smaller tumors whose histopathology was suggestive of a more benign condidysregulation of these cellular functions at the level of ligand binding, receptor signaling, or downstream intracellular signaltion-the tumor cells were less prone toward nuclear atypia and had more cytoplasm. Surprisingly, the proliferation index ing can have dramatic effects on cellular phenotype. Thus, it is not surprising that activating mutations, gene amplification, or in progenitor islets and solid tumors was comparable to those in wild-type RIP1-Tag2 mice, whereas the frequency of apoptosis epigenetic increases in gene expression that result in increased receptor kinase activity are associated with a number of different was 5-fold higher (Christofori et al., 1994; Naik et al., 1994) . Thus, IGF-II was implicated as a survival factor that conveyed human cancers.
Studies of a transgenic mouse model of cancer (RIP1-Tag2) resistance to apoptosis in the course of oncogene-induced tumorigenesis, congruent with results from cell culture studies on in which the SV40 T antigen oncoproteins are expressed in the ␤ cells of the pancreatic islets under the control of the rat insulin the c-myc oncogene (Harrington et al., 1994) . The expression and activity of IGF-II is subject to multiple promoter have proven instructive in delineating the cellular and molecular mechanisms of multistep tumorigenesis (Folkman levels of regulation. IGF-II is expressed widely during embryonic development in humans and rodents, but then transcription of and Bergers et al., 1998; Hager and Hanahan, 1999) . In particular, insulin-like growth factor-II (IGF-II) has been the Igf-II gene is variably downregulated and in some tissues extinguished after birth (Stewart and Rotwein, 1996) . In rodents, demonstrated to be a functional determinant of this tumorigenesis pathway, implicating signaling via a receptor tyrosine kinase, Igf-II gene expression is regulated in part by genomic imprinting of the maternal allele (DeChiara et al., 1991; Ferguson- 
Smith et the type I insulin-like growth factor receptor (IGF-1R). IGF-II is

S I G N I F I C A N C E
Tyrosine kinases have been widely implicated as causal agents for human cancers, motivating development of pharmacological inhibitors designed to abrogate their functional contributions. While elevated expression of IGF-1R and its ligands has been reported for many human tumors, the IGF signaling system has not been a prominent target for anticancer therapy. This report demonstrates that IGF-1R can induce tumors arising de novo in the pancreas of mice into an invasive and metastatic growth program. Regulatory determinants of invasion and metastasis remain elusive, and yet this is the hallmark of cancer that most often destines lethality. The possibility that IGF-1 receptor signaling conveys invasive and metastatic capability in human tumors deserves broader investigation, and prioritized development of pharmacological inhibitors may be warranted. Rappolee et al., 1992) . Interestingly, loss of imprinting involvement of the IGF-1 receptor in the RIP1-Tag2 model. The Igf-1R gene can be transcriptionally repressed by the p53 tumor and concomitant expression of both parental alleles is seen in SV40 T antigen-induced ␤ islet tumors (Christofori et al., 1995) .
suppressor protein in cultured cells , and thus binding and inactivation of p53 by the SV40 large T oncoBioavailability of the IGF-II protein is modulated in certain circumstances by a set of IGF binding proteins (IGF-BP), which protein (Ludlow, 1993) might be predicted to influence IGF-1R expression. Further, studies with transformed fibroblasts have can serve to prolong the half-life, sequester the protein within the extracellular matrix, and influence its association with receptors. demonstrated a role for IGF-1R in SV40 T antigen-mediated transformation (Sell et al., 1993) , revealing a "transforming reRelease of free IGF-II can be accomplished by proteolytic degradation of the IGF-BPs by proteases that include the kallikreingion" localized in the distinctive cytoplasmic signaling domain (discussed above) not contained in the otherwise structurally like serine proteases, cathepsins, and the matrix metalloproteinases (MMPs), each of which are also extensively regulated on similar insulin receptor. Further, a physical association between T antigen and IRS-1, a substrate of activated IGF-1R kinase, is multiple levels (Grimberg and Cohen, 2000) . IGF-II binds to two receptors, the IGF-1R, a transmembrane tyrosine kinase, and crucial for transformation of fibroblasts in culture (Zhou-Li et al., 1995) . In light of these considerations, we first examined IGF-2R, also known as the cation-dependent mannose-6 phosphate receptor; IGF-2R/M6P is thought to serve as a membrane in greater depth the endogenous expression of IGF-1R in the discrete stages of tumorigenesis, revealing upregulation in prebound reservoir or depot for IGF-II, as it appears in general to lack a capability for signal transduction (Braulke, 1999) . malignant stages and, provocatively, in the invasive regions of tumors. Then we upregulated expression of IGF-1R by producStudies in cell culture systems have revealed that IGF-1R can induce a number of "transformed" cellular phenotypes, ining transgenic mice in which the Igf-1R gene was under transcriptional control of the rat insulin promoter, and we examined cluding hyperproliferation, protection from apoptosis, and tumorigenicity Baserga et al., 1997) ; the effect of elevated levels IGF-1R in pancreatic ␤ cells coexpressing the oncoprotein, SV40 large T antigen. The results more recently, IGF-1R has been causally implicated in invasive and metastatic growth by its ability to convey such capabilities demonstrate that increased IGF-1R expression can accelerate progression through the stages of islet carcinogenesis, inducing on cultured epithelial cells (Dunn et al., 1998; Long et al., 1998b; Xie et al., 1999; Brodt et al., 2001) . IGF-1R can also be activated a more invasive and metastatic tumor phenotype. by the other insulin-like growth factor, IGF-I, as well as by insulin; these ligands have 10 times higher and 100 times lower affinities Results for IGF-1R than IGF-II, respectively. Furthermore, it has recently been demonstrated that all three ligands can bind to heterodimCharacterization of IGF-1R expression in the RIP1-Tag2 pathway ers composed of IGF-1R and an alternatively spliced isoform of the insulin receptor (IR-A), as well as to IR-A homodimers
In a previous study, semiquantitative RT-PCR analysis of islets representing distinct stages in the RIP-Tag2 progression path- (Frasca et al., 1999; Pandini et al., 1999; Vella et al., 2002) . While IGF-1R is structurally quite similar to the insulin receptor, it has a way suggested that levels of Igf-1R mRNA were increased approximately 2-fold upon the initiation of hyperproliferation, distinctive region within its cytoplasmic kinase domain (Dupont and LeRoith, 2001; Nakae et al., 2001) . Mutational analysis of the persisting similarly in subsequent stages of the pathway (Naik et al., 1994) . Cognizant of the range of lesions present at a given cytoplasmic portion of IGF-1R has revealed that its functional activities can be separated with mutations that individually abrotime and the potential for variability in expression at the cellular level, we have now performed immunohistochemical analysis gate induction of proliferation, tumorigenicity, and resistance to apoptosis (reviewed by Baserga et al., 1997) , and now also of IGF-1R expression after categorizing hematoxylin-and eosinstained RIP1-Tag2 islet lesions as either normal islets, hyperinvasion and metastasis (Brodt et al., 2001) . Thus, IGF ligand signaling emanates from this receptor into multiple intracellular plastic/dysplastic islets, angiogenic islets, islet tumors or insulinomas (IT) with well-defined margins and frequent fibrous effector circuits, each of which can influence a cellular function deemed important for tumor growth and progression.
capsules, carcinomas with focal regions of invasion (IC-1), or (rarely) broadly invasive carcinomas (IC-2). These categories, In regard to the insulin/IGF signaling system in the RIP-Tag pathway, the current state of knowledge is as follows. (1) The detailed in Table 1 , are based on gross morphological and detailed histopathological characteristics, founded upon on exten-IGF-1 and IGF-2/M6P receptors are both expressed at low but discernable levels in islet tumors and tumor-derived cell lines, sive experience with this model. IGF-1R staining was performed on adjacent sections, and with indications that the IGF-2/M6P depot/decoy receptor is more abundant, as shown by ligand binding and RNA analyses the levels and patterns of expression were assessed. Initially, RIP1-Tag2 islets, much as wild-type littermates (normal) (Figure (Naik et al., 1994) . (2) Expression of the insulin receptor gene is barely detectable in tumors (our unpublished observations).
1A), express a low, uniform level of IGF-1R, while both hyperplastic/dysplastic ( Figure 1B ) and angiogenic ( Figure 1C ) islets (3) Six of the known IGF-BP are expressed in normal islets and tumors at similar levels (Grewal et al., 1999) . (4) Insulin is have cells with a wide range of levels dispersed throughout the lesion in a seemingly random pattern. The benign islet tumors expressed at high levels (Hanahan, 1985; Efrat et al., 1988) , whereas IGF-I is expressed at very low levels (Naik et al., 1994) (IT), with well-defined margins and frequent fibrous capsules, evidence little or no detectable IGF-1R expression ( Figure 1D ). in islet tumors and tumor cell lines. And (5) as reviewed above, the dormant IGF-II gene is activated and comes to be highly By contrast, islet carcinomas (IC-1 and IC-2) exhibit distinctive IGF-1R expression at the tumor margins and invasive fronts expressed, and its expression is functionally significant, suggesting that IGF-II conveys an important, nonredundant signal ( Figure 1E ) and comparatively reduced levels in the interior (Figure 1F) . Notably, the immunohistochemical analysis, although in the context of oncogene-induced islet tumorigenesis. Several additional facts further motivated us to investigate the possible consistent with mRNA expression levels obtained by semiquan- titative RT-PCR, has revealed a striking variability between the Genetic upregulation of Igf-1R during RIP1-Tag2 carcinogenesis interior and periphery of invasive tumors and an apparent downregulation in the noninvasive islet tumors compared to the proWe sought to test the hypothesis that induction of IGF-II and increased expression of its receptor IGF-1R together play a role genitor lesions. The presence of high levels of IGF-1R in cells at the margins and within frankly invasive regions suggests a in islet carcinogenesis by perturbing expression of the receptor using transgenic mice. Previous studies had revealed that conrole for the IGF signaling in the acquisition and/or maintenance of invasive growth program.
stitutive upregulation of IGF-II in transgenic mice by expression stages of this pathway and its association with cell transformation, we sought to increase its levels throughout the stages of islet carcinogenesis. Several lines of RIP7-Igf-1R transgenic mice were generated, wherein a human Igf-1R cDNA was controlled by a version of the rat insulin gene promoter that consists of 9.5 kb of 5Ј flanking regulatory region and the 5Ј untranslated region (see Experimental Procedures). The mature IGF-1 receptor exists as a disulfide-linked heterotetramer composed of two ␣ and two ␤ chains. Expression levels of the transgene-encoded receptor were determined by immunoprecipitation of the intact receptor and Western blot analysis of the 130-135 kDa ␣ chain of the IGF-1R. One line, RIP7-Igf-1R
L1
, expressed IGF-1R in the pancreatic islets at a level comparable to that of the endogenous Igf-1R gene in a human breast carcinoma line, MCF-7, that has been used to study receptor signaling ( Figure 2A) ; this transgenic mouse line was selected for further characterization. Immunohistochemical staining for IGF-1R expression in paraffin-embedded pancreas sections from RIP7-Igf-1R single-transgenic mice demonstrated that IGF-1R was uniformly expressed on the plasma membrane of cells throughout the islets ( Figure  2B ). Expression of IGF-1R in the islet ␤ cells did not alter life expectancy or glucose homeostasis as determined by fasting glucose tolerance (data not shown). Consistent with the described role of IGF-1R in controlling cell size (Stewart and Rotwein, 1996) through the phosphoinositide 3-kinase-dependent serine/threonine protein kinase Akt (Tuttle et al., 2001) , transgenic ␤ cells exhibited an increased cytoplasmic to nuclear ratio ( Figure 2B ), indicating that transgenic expression of human Igf-1R gene resulted in sufficient levels of a functional receptor to activate intracellular signaling of a previously ascribed phenotype. There was no gross or histological evidence for a transformed phenotype in the RIP7-Igf-1R single-transgenic mice.
Next, the RIP7-Igf-1R transgenic mice were crossed with RIP1-Tag2 mice, and islets in young double-transgenic mice were examined by immunohistochemistry to confirm that IGF-1R was upregulated in the context of oncogene expression. Figure 2C shows that islet cells from 5-week-old double-transgenic RIP7-Igf-1R, RIP1-Tag2 mice have increased levels of IGF-1R, and receptor expression was more uniform throughout the islet than in the RIP1-Tag2 single-transgenic mice ( Figure  1) . Notably, even at 5 weeks of age, histological examination Figure 2C ) revealed marked morphological differences in the islets compared to the hyperplastic and early dysplastic stages Among several RIP7-Igf-1R transgenic lines produced, one (designated line #1 or RIP7-Igf1R L1 ) was chosen for this study after hu-IGF-1R protein was ( Figure 1B ) in age-matched littermate RIP1-Tag2 mice. The found to be expressed in islets at a similar level to that in a human breast boundary between some islets and adjacent exocrine pancrecancer-derived cell line, MCF-7 (A). Pancreatic islets were isolated, and atic tissue was poorly defined, and cells could be seen extending cell lysates were subjected to immunoprecipitation of intact IGF-1R followed into the exocrine pancreas. We went on to assess the impact by Western blotting to detect the 130-135 kDa IGF-1R ␣ chain. The apparent molecular weight of hu-IGF-1R was consistently found to be slightly lower of constitutive upregulation of IGF-1R on islet carcinogenesis. for tumor phenotype at regular intervals. Survival time of the RIP7-Igf-1R, RIP1-Tag2 mice was significantly decreased in comparison to the RIP1-Tag2 mice. The double-transgenic mice (n ϭ 12) lived on average 9.9 weeks in comparison to the 12.6 of the Igf-II cDNA under control of the rat insulin promoter did weeks typical for RIP1-Tag2 single-transgenic mice, in particular not enhance tumorigenesis (Naik, 1996) , suggesting that the for littermate siblings of the cross that generated the compound ligand levels achieved by activation and progressive upregulamice. (The difference in life span is statistically significant, with tion of the endogenous Igf-II gene were not limiting. In light of the complex patterns of expression of the Igf-1R gene in the p ϭ 0.0007 using the two-sample, two-tailed t test assuming The basis for these criteria came from exhaustive analysis here and elsewhere of RIP1-Tag2 transgenic mice. N*, histologically normal, but expressing the Tag oncogene.
unequal variance.) All double-transgenic mice were dead by 11 analyses of RIP1-Tag2 mice, or if the continuous backcrossing into the C57Bl/6 background (currently ϾN40) has enabled it. weeks, while single-transgenic littermates lived up to 16 weeks.
Comparison of the frequency of islet lesions in the doubleRemarkably, tumors were detectable in double-transgenic mice transgenic mice revealed marked differences ( Figure 4B ). At 5 at 7 weeks of age, significantly earlier than seen in the RIP1-weeks, the earliest time examined, only 60% of double-transTag2 single-transgenic mice. Tumor burden rapidly increased genic islet lesions were identifiable as normal or hyperplastic/ over 40-fold in the ensuing 2 week period (Table 2) , whereas dysplastic in comparison to almost 90% of islets in the singlethe single-transgenic RIP1-Tag2 mice had not yet developed transgenic mice. Moreover, at this time point, 30% of the lesions macroscopic tumors by this age.
in the double transgenic exhibit the tortuous, dilated vessels We next evaluated the temporal appearance and frequency characteristic of an angiogenic islet, which is significantly of tumor formation and of progenitor lesions in comparison to greater than the 12% seen in the single-transgenic RIP1-Tag2 the well-established parameters of the RIP1-Tag2 pathway. Islet mice. Remarkably, the more benign islet tumors characterized lesions from cohorts of RIP1-Tag2 controls and RIP7-Igf-1R, by the presence of a well-demarcating tumor-exocrine bound-RIP1-Tag2 mice were analyzed for the frequency of distinct ary were completely absent from the double-transgenic pancrestages of RIP1-Tag2 tumorigenesis using the criteria detailed ases at all time points. Instead, small invasive carcinomas were in Table 1. As described in earlier studies, the single RIP1-Tag2 detected in RIP7-Igf-1R, RIP1-Tag2 pancreases as early as 5 mice exhibit a temporal pattern of lesional progression that weeks of age ( Figure 3B ), and the frequency of the IC-2 lesions begins with normal, oncogene-positive islets, followed by the at this young age was higher than at any time point in the RIP1-appearance of hyperplastic/dysplastic and angiogenic islet leTag2 pathway ( Figure 4B ). Further, these invasive carcinomas sions, and finally solid tumors begin forming at 10-12 weeks.
came to constitute nearly 40% of all lesions detected in the The histological characteristics of the prototypical stages are pancreas of late-stage (9-to 10-week-old) double-transgenic described in Table 1 and illustrated in Figure 3A ; the abundance mice. of the various stages at ages 5-15 weeks is shown in Figure  4A . In the course of the extensive histological comparison performed here (Table 2) , we also detected uniformly invasive tu-IGF-1R enhances both proliferation and apoptosis in premalignant stages mors that lacked any vestige of the well-defined margins and frequent encapsulation of the typical solid tumors seen in the We have previously implicated both increased cell proliferation and varying rates of apoptosis in the progression of tumorigene-RIP1-Tag model. These small, uniformly invasive tumors (called invasive carcinoma type 2, or IC-2; see Table 1 and Figure 3A) sis in the RIP1-Tag2 pathway, and in particular have suggested that, as in many systems (Evan and Littlewood, 1998) , the balwere evident as early as 7 weeks of age, well before the more benign tumor types were detectable. It is presently unclear ance between the rates of cell proliferation and cell death govern tumor growth ; Bergers et al., 1998; Hager and whether this rare class of tumor was overlooked in the previous Typical examples of the stages evident in the pathways to islet carcinogenesis are shown for standard RIP1-Tag2 mice (A) and for the predominant pathway resulting from upregulation of IGF-1R in RIP1-Tag2, RIP7-Igf-1R double-transgenic mice (B). These morphologies are described in Table 1 and form the basis for the quantitative comparison of the temporal appearance and statistical abundance of the stages seen during progression to invasive carcinoma of the pancreatic islets. Note that the double-transgenic mice also develop IC-1 lesions, which are similar to that shown in A for RIP1-Tag2. Scale bars represent 20 m on all micrographs except the islet tumor and invasive carcinoma type 2 in A, where the scale is 40 m. . We assessed, therefore, both parameters in and/or IGF-II. In the double-transgenic mice, a significant increase in the frequencies of cells in cycle are seen in the hyperthe pancreases of double-transgenic mice at defined points during their lifetime. To assess proliferation frequencies, cells plastic/dysplastic and angiogenic lesions as compared with lesions from the single RIP1-Tag2 transgenic littermate. By incorporating BrdU were quantitated in the histologically distinct populations of islets and neoplastic lesions from nontransgenic contrast, the average proliferation rate seen in the tumors of the double-transgenic mice was not enhanced in comparison controls, from RIP7-Igf-1R, from RIP1-TAg2, and from doubletransgenic RIP7-Igf-1R, RIP1-TAg2 littermates ( Figure 5A ). Islets to the tumors in the RIP1-Tag2 single-transgenic mice.
To assess possible changes in the apoptotic rate as a consefrom the RIP7-Igf-1R single-transgenic mice possess a slightly elevated level of BrdU incorporation (6.4%) when compared quence of increasing the levels of IGF-1R, the TUNEL assay was performed on islet lesions from RIP1-Tag2 single-and to the nontransgenic littermate control (2.5%). The increase in proliferation rate in the Igf-1R single-transgenic mice is consis-RIP7-Igf-1R double-transgenic littermates. As seen in Figure  5B , the frequency of TUNEL positive apoptotic cells is increased tent with both the slight increase in islet size and the presence of a functional receptor that may be activated either in a ligandin normal, hyperplastic/dysplastic, and angiogenic lesions, but remains unaltered in the more advanced lesions in the double independent manner or by endogenous serum levels of IGF-I transgenics in comparison to the RIP1-Tag2 single-transgenic did not detect downregulation of E-cadherin in the islets of RIP7-Igf1R single-transgenic mice (not shown), which indicates mice. This result was unexpected, given the prediction that IGF-1R would signal resistance to apoptosis in response to that additional factors are necessary to effect its suppression; amongst the candidate cofactors in RIP1-Tag2 mice are the activation of IGF-II. Thus, elevated IGF-1R differentially impacts the growth phenotype, as reflected by the proliferation and induced IGF-II ligand, the expressed Tag oncoproteins, and the proliferative condition the oncogene elicits. apoptosis rates: it initially enhances apoptosis and less so proliferation in the earliest stages (compared to RIP1-Tag2 islets) where IGF-II is off or focally low (Christofori et al., 1994) ; then, it Elevated IGF-1R increases pancreatic islet metastasis comparatively upregulates proliferation in the angiogenic stage
Suppression of E-cadherin has also been associated with inwhen IGF-II levels are elevated; and finally, it has no impact on creased but still relatively low-frequency metastasis in the RIP1-either parameter in tumors.
Tag2 model (Perl et al., 1998) , motivating assessment of the metastatic phenotype in the Igf-1R double-transgenic mice. Indeed, the intrapancreatic lymph node (PLN) contained meta-IGF-1R downregulates E-cadherin Cell-cell adhesion is an important component of the normal static nodules in 77% of the double-transgenic mice analyzed; by comparison, 8.3% of single-transgenic RIP1-Tag2 mice had architecture of the islets, and loss of those intercellular contacts is postulated to be important for the development of malignancy. metastatic lesions (Table 3 ). More distant metastases were observed only occasionally in RIP1-Tag2, RIP7-Igf1R mice; we Prior studies have demonstrated that loss of the gap-junction protein E-cadherin is functionally involved in the transition from suspect the brief 10 week life span of the double-transgenic mice limited the opportunity for distant metastases to develop well-differentiated adenoma to invasive carcinoma in the RIP1-Tag2 pathway (Perl et al., 1998) . Furthermore, downregulation macroscopically. The intrapancreatic lymph node is the initial draining node for the pancreas (Cook, 1983 ; see also Mandriota of E-cadherin is associated with the malignant phenotype in many human cancers (Christofori and Semb, 1999; Cavallaro et al., 2001 , and references therein). This local lymph node has proved to be the predominant site for ␤ cell metastasis in RIPand Christofori, 2001) . Given the prevalence of highly invasive tumors in the double-transgenic mice, we sought to determine Tag2 mice, most notably in response to additional genetic perturbations. Thus, PLN metastasis was observed in the context whether E-cadherin expression was altered in the stages of islet of dominant-negative suppression of E-cadherin (Perl et al., carcinogenesis. Islets from single-and double-transgenic mice 1998), ablation of NCAM expression (Perl et al., 1999) , or coexwere stained for both E-cadherin and large T antigen, with the pression of the lymphangiogenic growth factor VEGF-C in the oncoprotein serving to visualize the neoplastic cells. Figures 6B oncogene-expressing ␤ cells (Mandriota et al., 2001 ). The patand 6D show a clear loss of E-cadherin expression in oncogeneterns and relatively low frequencies of metastasis observed in expressing cells in a relatively small double-transgenic islet lethese studies led to the proposition that multiple factors govern sion. A comparable lesion in the RIP1-Tag2 single-transgenic the capability for islet metastasis (Cavallaro and Christofori, mice shows no loss of E-cadherin expression ( Figures 6A and  2001) . The comparatively high frequency of metastasis pro-6C). Visual inspection revealed downregulation of E-cadherin duced by elevated levels of IGF-1R suggests that IGF-1R signalto be prevalent but not absolute in the numerous islet lesions ing affects more of the necessary conditions for the metastatic analyzed in the double-transgenic mice. To substantiate that growth program in addition to its clear association with downconclusion, we sought to quantitatively assess the apparent regulation of E-cadherin ( Figure 6 ). downregulation of E-cadherin by performing image analysis of the fluorescence intensity of E-cadherin immunostaining in islet lesions compared to adjacent normal exocrine pancreas. EvaluDiscussion ation of relative fluorescence intensity of E-cadherin in the different stages of the generic tumorigenesis pathway confirmed Motivated by the correlation of IGF-II gene activation with the onset of neoplastic proliferation in the RIP1-Tag2 tumorigenesis downregulation in both invasive carcinoma stages but not in progenitor islets or encapsulated islet tumors ( Figure 6E ). In pathway and by its functional association with resistance to apoptosis, we sought to investigate the role played by one of contrast, E-cadherin expression in RIP1-Tag2, RIP7-Igf-1R mice was decreased throughout tumorigenesis, in premalignant leits receptors, IGF-1R. The insulin-like growth factor receptor type 1 is a transmembrane tyrosine kinase with well-established sions as well as in invasive carcinomas ( Figure 6E ). Notably, we Using staging criteria summarized in Table 1 , lesions were classified at various time points in the life spans of RIP1-Tag2 (A) and RIP7-Igf-1R, RIP1-Tag2 double-transgenic (B) mice. Substantial numbers of lesions were evaluated at the noted ages, as summarized in Table 2 . Comparison of the islet lesions in the cohorts of RIP1-Tag2 and RIP7-Igf-1R, RIP1-Tag2 mice at 5, 7, and 9 weeks of age demonstrated a statistically significant shift toward invasive Figure 5 . Elevated levels of IGF-1R selectively increase proliferation and apocarcinomas (5 weeks, p ϭ 0.0304; 7 weeks, p ϭ 0.0518; 9 weeks, p ϭ 0.0051 ptosis in premalignat stages of islet carcinogenesis by the Wilcoxon score for variable grade).
The proliferation index (A) and the apoptotic index (B) in staged lesions ( with the transition from "normal" (oncogene-expressing) islets angiogenic islets, p ϭ 0.0005; and invasive carcinoma types 1 and 2 (combined), p ϭ 0.1493. Notably, increased levels of IGF-1R did not reduce to hyperplastic/dysplastic islets, and concomitant with the hetapoptosis, but rather increased both proliferation and apoptosis in the preerogeneous induction of its previously dormant ligand, IGF-II. these premalignant lesions to one where increased expression was localized to cells at the periphery and invasive fronts of established tumors, consistent with a role in promoting invasion. but probably not all of the regulatory equation. Seeking to probe Little or no expression was detectable in islet tumors with wellthe role of IGF-1R in this prototypical carcinogenesis pathway, defined margins and fibrous capsules, and expression was transgenic mice were generated that constitutively expressed patchy in the core of invasive carcinomas. We currently have IGF-1R at elevated levels in the islet ␤ cells of the pancreas. no clues into the dynamic regulation of endogenous IGF-1R
There was little effect on the islets of single-transgenic mice. levels in the stages of islet carcinogenesis. We suspect that By contrast, in the context of tumorigenesis, IGF-1R clearly the sporadic activation and heterogeneous expression of the accelerated neoplastic progression, most dramatically by prodormant (and imprinted) IGF-II gene (Christofori et al., 1994 (Christofori et al., , 1995 in ␤ cells expressing the T antigen oncogene may be part moting the capability for invasion and metastasis. 
. E-cadherin is downregulated early during tumorigenesis in RIP-7-Igf-1R, RIP1-Tag mice
A and B show immunostaining (green) for E-cadherin in hyperplastic/dysplastic islets of 5-week-old (A) single-and (B) double-transgenic mice, revealing marked suppression of E-cadherin in the latter. The regions devoid of E-cadherin in B are tumor cells expressing the large T oncoprotein, as revealed by coimmunostaining for Tag-expressing cells (labeled red); C and D show the same islets visualized for both E-cadherin and the oncogene. Downregulation of E-cadherin is prevalent (but heterogeneous) in all subsequent stages of the double-transgenic mice. Notably, the invasive regions of islet carcinomas in both single-and double-transgenic mice had reduced levels of E-cadherin (not shown), consistent with the results of Perl et al. (1998) . Scale bars are 20 m. E: Islet lesions from five RIP1-Tag2 (n ϭ 121 total lesions) and four RIP1-Tag2, RIP7-Igf-1R (n ϭ 76 total lesions) were categorized according to the criteria outlined in In designing this study, we predicted that elevating the levels signaling. Evaluation of proliferation and apoptosis frequencies in the different lesional stages demonstrated that both proliferaof IGF-1R throughout tumorigenesis would cause a generalized decrease in apoptosis at all stages, much as we observed when tion and apoptosis rates were significantly increased in the premalignant stages, contrary to expectations. The discrepancy the antiapoptotic factor Bcl-XL was similarly upregulated . The basis for this prediction came not only from between the protection from apoptosis afforded by IGF-II upregulation in the standard RIP1-Tag2 pathway and the increased the analysis of the phenotype in RIP1-Tag2, IGF-II null mice, but also from analysis of mice that had IGF-II constitutively apoptosis in progenitor lesions in the RIP1-Tag2, RIP7-Igf-1R transgenic mice may have a basis in the dynamics of signal upregulated. A RIP7-IGF-II transgenic line was produced and shown to express high levels of IGF-II in normal islet ␤ cells transduction. Ligand binding to IGF-1R has been shown to induce at least three intracellular signaling pathways: MAP kinase, without consequence; when crossbred to RIP1-Tag2, the double-transgenic mice had unchanged proliferative and apoptotic phospholipase C␥, and phosphoinositol 3-kinase. Mutational analyses of key residues in the cytoplasmic domain of the IGFprofiles during tumorigenesis (Naik, 1996) . From this, we concluded that the levels of IGF-II resulting from upregulation of 1R ␤ chain have demonstrated that it is possible to functionally separate the survival, proliferation, transformation, and invasive/ the endogenous IGF-II gene were sufficient to manifest its contributions to tumorigenesis, and therefore we postulated that metastatic responses (Baserga et al., 1997; Brodt et al., 2001) . Moreover, analysis of the MAP kinase pathway in other cell the low levels of its receptor might be limiting. Indeed, the results of elevating this IGF receptor suggest that is the case, but in culture models has shown that decisions between cell survival and apoptosis as well as between proliferation and cell cycle addition they have revealed an intriguing complexity to IGF-1R In this analysis, RIP1-Tag2 and RIP1-Tag2, RIP7-Igf-1R pancreases were collected, fixed, and serially sectioned, and tissue sections every 100 m were evaluated to reveal the pancreatic lymph nodes (PLN), which are the inital collecting point for the pancreatic lymphatic vasculature. The frequency of metastasis reported in generic RIP1-Tag mice has varied historically (Grant et al., 1991 , Perl et al., 1998 , perhaps as a function of genetic background, backcross generation, and age. To compare RIP1-Tag2 mice having the closest possible genetic background to the double transgenic mice at a similar stage of disease progression, a cohort of single transgenic RIP1-Tag2 littermates were sacrificed somewhat later than when their double transgenic siblings were at endstage and both were analyzed. Separately, endstage RIP1-Tag mice from the standard breeding colony were evaluated. Histological analyses by H&E, confirmed by insulin immunostaining, established the presence of metastatic nodules inside the lymph nodes. The difference in metastatic frequency is statistically significant compared to both RIP1-Tag2 cohorts (p ϭ 0.0022 for the double transgenic mice versus RIP1-Tag littermates, and p ϭ 0.0022 versus RIP1-Tag mice from the colony, as determined using the Fisher's Exact test).
arrest can be effected through alternative signaling thresholds downregulated (Perl et al., 1998) . Our interpretation is that signals from IGF-1R and from the Tag oncogene collaborate, likely determined by both the strength and duration of the activating signal (Woods et al., 1997; Cook et al., 1999) . Based on these with additional agents (perhaps IGF-II), to effect E-cadherin downregulation, a possibility that deserves future investigation. considerations, we envision that the modest upregulation of IGF-1R in premalignant lesions of RIP1-Tag2 single-transgenic
It is pertinent to consider other candidate effectors of invasion and metastasis elicited by IGF-1R signaling, as there is mice establishes the receptor at a level that primarily signals antiapoptosis. Then, when the receptor level is further elevated reason to suspect that suppression of E-cadherin is necessary but not sufficient. One rationale involves the comparatively low via the transgene, a threshold is crossed such that the predominant signaling output is biased to the proliferative and invasive/ frequency of metastasis seen when E-cadherin was suppressed (Perl et al., 1998) relative to when IGF-1R levels were elevated metastatic effector circuits instead of antiapoptosis. We suspect that the invasive effector signal is also activated (but perhaps (this study), suggesting that IGF-1R signaling regulates other effectors of invasion. A second is that invasive carcinomas arise to a lesser extent) by the focally elevated IGF-1R seen in the invasive regions of carcinomas of RIP1-Tag2 single-transgenic much earlier and at higher frequency in the case of IGF-1R upregulation than in that involving forcible E-cadherin downregmice. Additional considerations involve the heterogeneous expression of IGF-II, the potential of IGF binding proteins to moduulation. Several previous studies have identified candidate effectors of invasive and metastatic capabilities regulated by IGFlate its bioavailability, and the possible involvement of the other IGF-1R ligands, IGF-I, and insulin. Moreover, the insulin receptor 1R in cultured cells: Dunn et al. (2001) found that urokinase was upregulated by IGF-1R in the MDA-MB-213 human breast is now known to have an alternative isoform with higher IGF affinity (Frasca et al., 1999; Vella et al., 2002) and the potential cancer line, and Long et al. (1998a) reported IGF-1R regulation of MMP-2 in a variant Lewis lung carcinoma line, whereas Mira to make functional heterodimers with IGF-1R (Pandini et al., 1999) . It will be of interest to assess the possible contributions et al. (1999) found that MMP-9 was induced by IGF-I in MCF-7 human breast cancer cells. Extracellular proteases have long of these members of the IGF axis to islet carcinogenesis. been implicated in invasion and metastasis, and as such these are attractive candidates that bear investigation in the RIP1-E-cadherin and other effectors of IGF-1R invasive and metastatic signaling Tag2, RIP7-Igf-1R tumorigenesis pathway. A counterpoint is that neither urokinase, MMP-2, nor MMP-9 appear to be individ-IGF-1R signaling has long been associated with cellular transformation and more recently with invasion and metastasis (Dunn ually important for induction of the invasive phenotype in islet carcinomas arising in the wild-type RIP1-Tag2 model. The eviet al., 1998; Long et al., 1998b; Xie et al., 1999; Brodt et al., 2001) . So too has suppression of E-cadherin, a cell adhesion dence comes from gene knockout mice lacking each of these proteinases and from pharmacological inhibition studies with molecule causally associated with invasion in this model and in a variety of human cancers (Christofori and Semb, 1999;  MMP inhibitors that target MMP-2 and MMP-9. When gene knockouts for urokinase (uPA), MMP-2, or MMP-9 were crossCavallaro and Christofori, 2001). Two previous reports have suggested a possible connection between E-cadherin and IGFbred into the RIP-Tag2, and the protease null mice were analyzed, the surprising result was that mice lacking any one of 1R signaling: Andre et al. (1999) and Playford et al. (2000) each reported that IGF-I ligand increased tyrosine phosphorylation these three proteases still developed highly invasive islet carcinomas (Bergers et al., 2000) ; MMP-2 and MMP-9 were, howof ␤-catenin in colon carcinoma cell lines, resulting in dissociation of E-cadherin from the plasma membrane, thereby supever, demonstrably important for tumor growth. Furthermore, treatment of RIP1-Tag2 mice with MMP inhibitors also impaired pressing its cell adhesion function. Here, by elevating IGF-1R levels in the RIP-Tag2 pathway, we have shown that E-cadherin tumor growth but did not affect progression to invasive carcinomas (Bergers et al., 1999 (Bergers et al., , 2000 . Finally, MMP-9 was not exis downregulated early and far more prevalently that in the unperturbed pathway, where IGF-1R levels are more variable. Nopressed by the islet tumor cells coexpressing the Tag oncogene, IGF-II, and IGF-1R; rather, it is expressed in perivascular intably, the data presented above show that IGF-1R is expressed at the highest levels in single RIP1-Tag2 tumors at the boundflammatory cells (Bergers et al., 2000 , and unpublished observations of the Hanahan laboratory). While these data argue against aries and in invasive regions, where E-cadherin is known to be their involvement in local invasion in the pancreas, we cannot exclude that one or another of these proteinases will prove to be induced in metastatic islet tumor cells and functionally involved therein; the possibility deserves future investigation. Similarly, the suggestions that IGF-1R-induced invasiveness is dependent on upregulation of integrins (Mira et al., 1999) or phosphorylation of ␤-catenin and IRS-1 (Playford et al., 2000) should be considered. While these candidates may or may not prove to be the implicit cofactors or the functional effectors of E-cadherin suppression that are necessary for signaling of invasion and metastasis by IGF-1R, we expect the critical genes will be identified as new candidates presented from other systems or by comparative analysis in the various RIP-Tag models, who are then confirmed via genetic manipulation of their functionality during islet carcinogenesis.
IGF-1R directs tumorigenesis into an invasive growth program
In the course of analyzing the effects of elevating the levels of the IGF-1R throughout the well-established RIP1-Tag2 tumorigenesis pathway, the complete spectrum of lesions was thoroughly examined at three different time points (5, 7, and 9 weeks of age) in both the RIP1-Tag2 single-and RIP1-Tag2, RIP7-Igf-1R double-transgenic mice. The analysis of the single-transgenic mice confirmed the multistep paradigm proposed in earlier , 1988) , the islets were found to be histologically "nortics of lesional stages that appear in the pancreas of RIP1-Tag2 mice sugmal" until 3-4 weeks after birth, when a subset activated diffuse gests a branched pathway to invasive carcinoma, as shown in A; the stages ␤ cell hyperproliferation and concomitant apoptosis, developing are described in Table 1 and exemplified in Figure 3A . The prevailing evithe histological characteristics of hyperplasia and dysplasia. Of dence from this study and those of Christofori and colleagues implicates a major pathway wherein angiogenic dysplasias ("angiogenic islets") in RIP1-these lesions, a subset switched on angiogenesis, as evidenced Tag2 mice progress predominantly to islet tumors with well-defined margins by the dilated, tortuous vasculature and microhemorrhaging that lack invasion. Invasive regions subsequently appear, focally projecting characteristic of the angiogenic islet stage. At 5 weeks, all of out of such well-defined islet tumors, producing the invasive carcinoma these lesions are evident (Figures 3 and 4) . Islet tumors with type 1 (IC-1), which is relatively frequent (8%-10% of islets at risk at 15 weeks). An exhaustive histopathological analysis (Table 2 ) of RIP1-Tag single-transwell-defined margins and often capsules (IT) begin appearing genic mice has revealed a less-frequent carcinoma that lacks evidence at about 10 weeks, which then progress into tumors with focal for a margin or capsule (invasive carcinoma type 2, IC-2). Both carcinoma invasive regions (invasive carcinoma type 1, or IC-1), representtypes may produce the infrequent metastases observed. Elevated expresing at endstage approximately 5% of the 400 pancreatic islets sion of IGF-1R biases the branched pathway in favor of the otherwise minor "at risk." In addition, our analysis of 7-and 9-week-old RIP1-IC-2 branch (B), in part by suppressing expression of E-cadherin, producing a high incidence of broadly invasive carcinomas (40% of the focal islet Tag2 mice has revealed the presence of rare, highly invasive lesions at 9 weeks) and frequent local metastasis. These results, considered lesions that appear to have developed in the absence of progeniin the context of independent studies in other experimental systems, suggest tor tumors (IT) having well-defined margins. We now propose that elevated levels of IGF-1R may be a causal factor in neoplastic progresthis class of tumor arises via a heretofore unappreciated minor sion to highly invasive and metastatic phenotypes in settings of natural carcinogenesis.
pathway leading directly from angiogenic islets to widely invasive carcinomas that lack both an identifiable capsule and a clear margin with adjacent exocrine pancreas (IC-2). In Figure  7A , we have diagrammed this modification of RIP1-Tag2 pathnomas, with a spectrum of sizes ranging from microscopic (simiway, in which a branch point at the hyperplastic/dysplastic or lar to islets) to macroscopic. By contrast, 9-week-old RIP1-Tag angiogenic islet stage shunts a subset of progenitor lesions single-transgenic mice lacked macroscopic tumors of any class away from the path to encapsulated islet tumors, directing them (IT, IC-1, or IC-2) and had at most 1-2 microscopic IC-2 lesions. instead to form highly invasive carcinomas.
These comparisons make an important point, namely that the The existence of a branch in the tumorigenesis pathway highly invasive carcinomas induced by IGF-1R do not reflect a that leads directly to invasive carcinoma is corroborated by our novel phenotype peculiar to the RIP1-Tag2, RIP7-Igf-1R mice analysis of tumorigenesis in the double-transgenic RIP1-Tag2, overexpressing IGF-1R. Rather, the IGF-1R transgene biases RIP7-Igf-1R mice. Elevated levels of IGF-1R accelerated the carcinogenesis in favor of a newly appreciated branch of the temporal appearance and abundance of hyperplastic/dysplastic pathway that is also evident in single-transgenic RIP1-Tag2 and angiogenic islet lesions and of highly invasive carcinomas mice. Our revised view of the islet carcinogenesis pathway that (IC-2). There was, remarkably, a complete absence of benign unfolds in RIP1-Tag mice diagrammed in Figure 7 , both for islet tumors (IT). At 9 weeks, ‫%04ف‬ of the islets in the doubletransgenic mice had already progressed to highly invasive carcithe RIP1-Tag2 single-transgenic case ( Figure 7A ) and for the tory sequences included the proximal promoter-enhancer region and most illustrative perturbation whereby the levels of IGF-1R were forcof the 5Ј untranslated region of the transcribed portion of the gene with its ibly elevated ( Figure 7B ). pharmacological inhibitors of IGF-1R signaling.
Bromodeoxyuridine labeling Experimental procedures
Mice were injected intraperitoneally with 5-bromo-2Ј-deoxyuridine (Sigma) to give a final dose of 100 g BrdU/g body weight and euthanized 2 hr Transgenic mice later. Tissues were collected and prepared as described above for paraffin The RIP7-IGF-1R transgene utilized a full-length cDNA clone of the human embedding. The 5-Bromo-2Ј-Deoxy-Uridine Labeling and Detection Kit II insulin-like growth factor type 1 (Igf-1R) gene (Ullrich et al., 1986 ) that had (Roche) was used with the following modifications. After deparaffinization been shown to be biologically active when transfected in an expression and rehydration, antigen retrieval (Citra Solution, Biogenex) was performed vector into cultured mammalian cells (Yamasaki et al., 1991) . The Igf-1R according to the manufacturer's protocol. Anti-BrdU was detected with cDNA was inserted as a 4.4. kb fragment into the RIP7 vector (Naik et al., biotinylated goat anti-mouse IgG (1:200; Vector Laboratories) and then pro-1996), which consists of ‫01ف‬ kb of the 5Ј flanking region of the rat insulin II gene carried in a Bluescript-derived plasmid vector; the insulin gene regulacessed for biotinylated antibodies as described above.
Bergers, G., Hanahan, D., and Coussens, L.M. (1998) . Angiogenesis and TUNEL staining apoptosis are cellular parameters of neoplastic progression in transgenic TdT-mediated dUTP-digoxigenin nick-end labeling was done on paraformaltumor models of tumorigenesis. Int. J. Dev. Biol. 42, 995-1002. dehyde-fixed, paraffin-embedded tissues. Sections were prepared as described above and preincubated with Proteinase K solution (undiluted, Dako) Bergers, G., Javaharian, K., Folkman, J., and . Effects for 3 min followed by an incubation with 0.15 M NaCl, 0.5% bovine serum of angiogenesis inhibitors on multistage carcinogenesis in mice. Science albumin in TdT buffer (Invitrogen). Sections were incubated with terminal 284, 808-812. deoxynucleotidyl transferase (200 U/ml; Invitrogen) and alkali-stable digoxiBergers, G., Brekken, R., McMahon, J., Vu, T., Itoh, T., Tamaki, K., Tanzawa, genin-conjugated dUTP (2 M; Boehringer-Mannheim) diluted in TdT buffer.
K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000) . Matrix metalloFinally, sections were incubated with horseradish peroxidase-conjugated proteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Fab fragments of sheep anti-digoxigenin-POD (5 U/ml; Roche Christofori, G., Naik, P., and Hanahan, D. (1994) . A second signal supplied protein was boiled in loading buffer with ␤-2 mercaptoethanol and run on by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature a 8% SDS-polyacrylamide gel. Proteins were blotted on Immobilon-P mem-369, 414-418. brane (Millipore) and probed with the rabbit polyclonal anti-IGF-1R (human, Christofori, G., Naik, P., and Hanahan, D. (1995) . Deregulation of both immouse, and rat IGF-1R ␣ chain; Santa Cruz Biotechnology) in 5% milk printed and expressed alleles of the insulin-like growth factor 2 gene during powder in 20 mM Tris, 137 mM NaCl, 0.1% Tween-20. The blot was devel-␤-cell tumorigenesis. Nat. Genet. 10, [196] [197] [198] [199] [200] [201] . oped with horseradish peroxidase-conjugated goat anti-rabbit IgG (BioRad) and ECL (Amersham).
Comoglio, P.M., Tamagnone (1999) . The repertoire of Fos and Jun measured using the Openlab software (Improvision) as mean fluorescence proteins expressed during the G1 phase of the cell cycle is determined by intensity (pixels). To permit comparison between different areas of the same the duration of mitogen-activated protein kinase activation. Mol. Cell. Biol. slide and different slides, an adjacent region-of-interest was defined in the 19, 330-341. exocrine tissue for each islet lesion, and the ratio of fluorescence intensity of islet lesion to adjacent exocrine pancreas was determined. DeChiara, T.M., Robertson, E.J., and Efstratiadis, A. (1991) . Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64, 849-859.
